Trials / Completed
CompletedNCT02716220
Pre-market Study of the DREAMS 2G Drug Eluting Absorbable Metal Scaffold (BIOSOLVE-III)
BIOTRONIKS - Acute Performance Of a Drug Eluting Absorbable Metal Scaffold (DREAMS 2G) in Patients With de Novo Lesions in NatiVE Coronary Arteries: BIOSOLVE-III
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 61 (actual)
- Sponsor
- Biotronik AG · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
BIOSOLVE-III Study is a pre-market, prospective, multi-center trial to assess the acute clinical performance of the DREAMS 2G Drug-Eluting Coronary Scaffold in de novo coronary artery lesions.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Percutaneous Coronary Intervention | Implanttaion fo the DREAMS 2G Scaffold |
Timeline
- Start date
- 2016-03-01
- Primary completion
- 2017-12-01
- Completion
- 2019-08-01
- First posted
- 2016-03-23
- Last updated
- 2020-01-18
Locations
8 sites across 4 countries: Belgium, Germany, Netherlands, Switzerland
Source: ClinicalTrials.gov record NCT02716220. Inclusion in this directory is not an endorsement.